The immunotherapy combination of tremelimumab and durvalumab has shown surprising efficacy, particularly as a second-line treatment option for patients with pleural…
The mesothelioma program at University of Chicago Medicine is recruiting patients for its latest clinical trial involving olaparib, an oral chemotherapy drug…
A dual registry analysis by the esteemed Duke University Medical Center has concluded that adjuvant hemithoracic radiation does not improve survival when…
Dr. Maurizio D’Incalci already has seen Tumor Treating Fields working for patients with malignant pleural mesothelioma, and applauded the U.S. Food and…
Memorial Sloan Kettering Cancer Center continues its drive toward a future that may involve innovative CAR T-cell therapy as part of standard-of-care treatment…
Researchers at MD Anderson Cancer Center in Houston have uncovered a new, promising treatment option for patients with peritoneal mesothelioma, potentially filling…
It comes as no surprise that immunotherapy is the common theme of the latest batch of the Mesothelioma Applied Research Foundation’s $100,000 grants.
A novel, targeted cancer vaccine combined with the immunotherapy drug Opdivo has shown surprising efficacy for mesothelioma patients whose disease no longer…
Your web browser is no longer supported by Microsoft. Update your browser for more security, speed and compatibility.
If you are looking for mesothelioma support, please contact our Patient Advocates at (855) 404-4592
Reviewed & Fact-Checked
This page was reviewed by:
Fact-checked and verified content:
Our fact-checking process begins with a thorough review of all sources to ensure they are high quality. Then we cross-check the facts with original medical or scientific reports published by those sources, or we validate the facts with reputable news organizations, medical and scientific experts and other health experts. Each page includes all sources for full transparency.
Please read our editorial guidelines to learn more about our content creation and review process.
